Home›Trial›NCT06430866
🔬NCT06430866Phase 3ACTIVE NOT RECRUITING

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

Study Summary

The primary objective of this study is to demonstrate pharmacokinetic (PK) similarity ABP 234 with pembrolizumab.

Conditions
Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
Interventions / Drugs
ABP 234Pembrolizumab
View on ClinicalTrials.gov ↗
Sponsor
AMGN
Amgen Inc
Biologics
F33/100
Study Details
Enrollment163 participants
Primary Completion—
Lead SponsorAmgen
Data Retrieved2026-04-13 18:29:34.158173+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.